INSIDE

World TB Day -March 24, 2017
World TB Day is recognized each year on March 24, which commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus that causes tuberculosis (TB). World TB Day provides an opportunity to raise awareness about TB and the measures needed to tackle this devastating disease. In 2017, for the second year, CDC will join the global Stop TB Partnership in adopting the World TB Day theme "Unite to End TB."
In 2016, a total of 9,287 new TB cases occurred in the United States (incidence of 2.9 cases per 100,000 persons) (1), a decrease from the 2015 case count and incidence. This 2016 provisional case count represents the lowest number of TB cases recorded since reporting began in 1953. However, data suggest that current strategies will not be sufficient to reach the goal of U.S. TB elimination during this century (2) .
CDC is committed to eliminating TB in the United States. This will require expanded initiatives, both in the United States and globally. These initiatives must maintain and strengthen existing strategies for diagnosing and treating persons with TB disease and also increase testing and treatment of persons with latent TB infection as outlined in CDC recommendations and the 2016 recommendation from the U.S. Preventive Services Task Force (USPSTF) (3, 4) . Additional information about World TB Day and CDC's TB elimination activities is available on CDC's TB website (https://www.cdc.gov/tb/worldtbday).
In 2016, a total of 9,287 new tuberculosis (TB) cases were reported in the United States; this provisional* count represents the lowest number of U.S. TB cases on record and a 2.7% decrease from 2015 (1). The 2016 TB incidence of 2.9 cases per 100,000 persons represents a slight decrease compared with 2015 (-3.4%) (Figure) . However, epidemiologic modeling demonstrates that if similar slow rates of decline continue, the goal of U.S. TB elimination will not be reached during this century (2) . Although current programs to identify and treat active TB disease must be maintained and strengthened, increased measures to identify and treat latent TB infection (LTBI) among populations at high risk are also needed to accelerate progress toward TB elimination. Figure) . Incidence among foreign-born persons (14.6 cases per 100,000) decreased 3.2% from 2015, but was approximately 14 times the incidence among U.S.-born persons.
Among U.S.-born persons, TB incidence remained stable among non-Hispanic whites (0.5 cases per 100,000) and Asians Table 2) . TB incidence has decreased or remained stable since 2013 in all U.S.-born racial/ethnic groups except American Indian/Alaska Natives and Native Hawaiian/Pacific Islanders, which experienced increases during this period before decreasing in 2016.
Among foreign-born persons, the highest TB incidence in 2016 was among Asians (26.9 cases per 100,000), followed by non-Hispanic blacks (22.3) and Hispanics (10.0), and most foreign-born racial/ethnic groups have experienced gradual decreases between 2013 and 2016. The top five countries of origin for foreign-born persons reported with TB disease in the United States were Mexico (1,194 cases, 18.9% of all foreign-born cases), the Philippines (795, 12.6%), India (593, † https://www.cdc.gov/tb/programs/rvct/instructionmanual.pdf. § U.S.-born persons are defined as persons who were born in the United States or a U.S. island area or born abroad to a U.S. citizen parent or parents. All others, including those who have become U.S. citizens through naturalization, are considered to be foreign-born persons.
9.4%), Vietnam (496, 7.9%), and China (383, 6.1%). Cases in persons born in these countries accounted for 54.9% of all cases among foreign-born persons.
HIV status was known for 86.7% of TB cases reported in 2016; among these patients, 5.8% had documented HIV coinfection. Living in congregate settings such as shelters, longterm care facilities, and correctional facilities is a known risk factor for TB exposure (4) , and complete data on these risk factors were available for >93% of cases. Among these, 4.6% of patients reported having experienced homelessness in the year preceding diagnosis. In addition, 1.8% were reported as residing in a long-term care facility, and 3.5% were reported as being confined in a correctional facility at the time of diagnosis.
The most recent year for which complete drug-susceptibility data are available is 2015; the data include test results for 98.7% of culture-confirmed TB cases. In 2015, 88 cases of multidrugresistant TB ¶ occurred; multidrug-resistant TB accounted for 0.4% and 1.2% of culture-confirmed TB cases among U.S.-born and foreign-born persons, respectively. Among the 88 multidrug-resistant TB cases, 72 (81.8%) occurred in persons ¶ Multidrug-resistant tuberculosis (TB) is defined by the World Health Organization as a case of TB in a person with a Mycobacterium tuberculosis isolate resistant to at least isoniazid and rifampin. * Incidence calculated per 100,000 persons. † Case counts based on data from the National Tuberculosis Surveillance System as of February 17, 2017. The Current Population Survey (https://www.census.gov/ programs-surveys/cps.html) provides the population denominators used to calculate TB incidence according to national origin and racial/ ethnic group. § U.S.-born persons were born in the United States or a U.S. island area or born abroad to a U.S. citizen parent or parents. All others, including naturalized U.S. citizens, are considered to be foreign-born persons. ¶ Incidence was not calculated for these categories. ** No cases for foreign-born American Indian/Alaska Native population occurred in 2014.
with no reported prior history of TB disease. In 2015, one case of extensively drug-resistant TB** was reported.
Discussion
Provisional data for 2016 demonstrate a slight decline in both TB case count and incidence in the United States compared with 2015. However, previously published epidemiologic modeling suggests that maintaining similar rates of decline in the future will not be sufficient to achieve TB elimination in the United States during this century (2) . Current TB control priorities, including early identification of TB cases, prompt institution of appropriate treatment, and identification of exposed contacts remain critical to preventing a resurgence of TB; to achieve TB elimination, expanded measures and new strategies are needed. Epidemiologic models demonstrate that identifying and treating persons with LTBI (a condition that occurs when a person is infected with Mycobacterium tuberculosis without signs and symptoms, or radiographic or bacteriologic evidence of TB disease) is critical to accomplishing the goal of TB elimination (2) . This strategy is consistent with CDC recommendations as well as 2016 recommendations from the U.S. Preventive Services Task Force (USPSTF) to screen for LTBI with tests such as the tuberculin skin test or interferon-gamma release assay in populations that are at increased risk for TB (4, 5) . The USPSTF characterizes populations at increased risk as those persons who were born in, or formerly resided in, countries with increased TB prevalence as defined by the World Health Organization (WHO) (6); and persons who currently live in, or have lived in high-risk congregate settings such as homeless shelters, correctional facilities, and long-term care facilities.
In 2016, four of the top five countries of origin for foreignborn persons reported with TB disease were considered high TB burden countries by WHO (China, India, Philippines, Vietnam), and accounted for 36% of incident TB cases among foreign-born persons in the United States (6). Because approximately 90% of TB cases in foreign-born persons in the United States are attributable to reactivation of LTBI, targeted testing for and treatment of LTBI among foreign-born persons from countries with high TB prevalence could be an effective strategy to decrease TB incidence (7) . The current recommendation from the USPSTF to test persons at increased risk regardless of length of time in the United States is in keeping with evidence that reactivation of LTBI remains a substantial concern, even in foreign-born persons who have lived in the United States for many years (8, 9) .
Workers in high-risk congregate settings are also at increased risk for TB and should be included as part of a targeted testing and treatment approach (4) . Other persons at risk for TB infection or for progression from LTBI to TB disease who should also be included in this strategy include close contacts of infectious TB patients, persons with immunosuppression, persons with other medical conditions (e.g., diabetes mellitus, chronic renal failure, or silicosis) associated with progression from LTBI to TB disease, and persons with fibrotic changes on a chest radiograph suggestive of inactive TB disease (4) .
The findings in this report are subject to at least two limitations. First, this analysis is limited to reported provisional case counts and incidence rates for 2016. Second, incidence rates are calculated based on estimated population denominators for 2016.
Although TB case counts and incidence are decreasing in the United States, progress is insufficient to achieve in this century the goal of TB elimination. Measures to diagnose and treat active TB disease must continue, and new strategies aimed at accelerating progress toward TB elimination in the United States, such as targeted testing for and treatment of LTBI, should also be employed. Expanded partnerships with health care providers outside of the public health sector will be important in effectively implementing such a strategy.
What are the implications for public health practice?
Current strategies are effective in controlling TB, but not sufficient to promote progress toward the goal of eliminating TB in the United States. Current TB control priorities remain important to prevent a resurgence of TB, but expanded measures and new strategies are needed to achieve TB elimination. Targeted testing and treatment of latent TB infection in populations at high risk for TB are key strategies for lowering incidence and moving toward elimination.
** Extensively drug-resistant TB is defined by the World Health Organization as a case of TB in a person with a Mycobacterium tuberculosis isolate with resistance to at least isoniazid and rifampin among first-line anti-TB drugs, resistance to any fluoroquinolone (e.g., ciprofloxacin or ofloxacin), and resistance to at least one of three second-line injectable drugs (i.e., amikacin, capreomycin, or kanamycin).
